Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival

BACKGROUND: Recurrence-free survival (RFS) and overall survival (OS) data for adjuvant nivolumab versus placebo (proxy for routine surveillance) in patients with high-risk, resected melanoma are lacking. This post hoc, indirect treatment comparison (ITC) used pooled data from the phase 3 EORTC 18,07...

Descripción completa

Detalles Bibliográficos
Autores principales: Weber, Jeffrey S., Poretta, Tayla, Stwalley, Brian D., Sakkal, Leon A., Du, Ella X., Wang, Travis, Chen, Yan, Wang, Yan, Betts, Keith A., Shoushtari, Alexander N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025222/
https://www.ncbi.nlm.nih.gov/pubmed/36197494
http://dx.doi.org/10.1007/s00262-022-03302-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025222/
https://www.ncbi.nlm.nih.gov/pubmed/36197494
http://dx.doi.org/10.1007/s00262-022-03302-5

Ejemplares similares